Good growth in sales and profitability with continuous concentration on strategic investments. 

Period January - June

  · Growth in local currency was 14 percent. Sales amounted to SEK 149 (142) million, corresponding to an increase of 5 percent in SEK.
  · Operating income before research and development costs increased by 14 percent and amounted to SEK 41 (36) million.
  · Operating income (EBIT) increased by 13 percent and amounted to SEK 19 (17) million. The operating margin was 13 (12) percent.
  · The Group's net income amounted to SEK 19 (16) million.

Quarter in brief

  · Growth in local currency was 13 percent. Sales amounted to SEK 73 (70) million, corresponding to an increase of 4 percent in SEK.
  · Operating income before research and development costs increased by 7 percent and amounted to SEK 20 (19) million.
  · Operating income (EBIT) increased by 11 percent and amounted to SEK 9 (8) million. The operating margin was 12 (11) percent.
  · The Group's net income amounted to SEK 9 (7) million, which gives earnings per share of SEK 0.48 (0.38).
  · The cash flow from operating activities was SEK 13 (12).
  · Dividend paid by 0.50 SEK per share.
  · The clinical study on STEEN Solution™ presented good treatment results.
  · Collaboration agreement with University of Melbourne regarding development of stem cell media.
  · Collaboration agreement with the Danish company HertART Aps regarding development of fertility products.  
  · Good clinical results from Swemed Sense™ multicenter study presented.

July 15, 2010

Gothenburg

Magnus Nilsson

CEO

Queries should be addressed to:

Magnus Nilsson, CEO; phone +46 31 721 80 61

Eva Nilsagård, CFO, phone +46 31 721 80 13